SERVING OVERLOOKED PATIENTS

Serial Number 97388326
733

Registration Progress

Application Filed
Apr 29, 2022
Under Examination
Apr 18, 2023
Approved for Publication
Feb 21, 2023
Published for Opposition
Feb 21, 2023
Registered

Trademark Image

SERVING OVERLOOKED PATIENTS

Basic Information

Serial Number
97388326
Filing Date
April 29, 2022
Published for Opposition
February 21, 2023
Drawing Code
4

Status Summary

Current Status
Active
Status Code
733
Status Date
Jul 21, 2025
Application
Pending
Classes
005

Rights Holder

Azurity Pharmaceuticals, Inc.

03
Address
8 Cabot Road, Suite 2000
Woburn, MA 01801

Ownership History

Azurity Pharmaceuticals, Inc.

Original Applicant
03
Woburn, MA

Azurity Pharmaceuticals, Inc.

Owner at Publication
03
Woburn, MA

Legal Representation

Attorney
Douglas R. Wolf

USPTO Deadlines

No Upcoming Deadlines

No upcoming deadlines found for this trademark.

Application History

26 events
Date Code Type Description Documents
Jul 22, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jul 21, 2025 EX4G S SOU EXTENSION 4 GRANTED Loading...
Apr 3, 2025 EXT4 S SOU EXTENSION 4 FILED Loading...
Jul 21, 2025 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Apr 4, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Feb 19, 2025 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Oct 16, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Oct 16, 2024 EX3G S SOU EXTENSION 3 GRANTED Loading...
Oct 16, 2024 EXT3 S SOU EXTENSION 3 FILED Loading...
Oct 16, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Feb 22, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Feb 21, 2024 EX2G S SOU EXTENSION 2 GRANTED Loading...
Feb 21, 2024 EXT2 S SOU EXTENSION 2 FILED Loading...
Feb 21, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Oct 10, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Oct 6, 2023 EX1G S SOU EXTENSION 1 GRANTED Loading...
Oct 6, 2023 EXT1 S SOU EXTENSION 1 FILED Loading...
Oct 6, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Apr 18, 2023 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Feb 21, 2023 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Feb 21, 2023 PUBO A PUBLISHED FOR OPPOSITION Loading...
Feb 1, 2023 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jan 18, 2023 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jan 10, 2023 DOCK D ASSIGNED TO EXAMINER Loading...
May 4, 2022 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
May 3, 2022 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
pharmaceutical preparations sold as a kit for use by pharmacists and physicians in creating compounded hormone replacement medicines, topical anti-inflammatory and ultrasound gels, pain and gastrointestinal disorders treatment medicines, and anti-inflammatory, antimicrobial, and antifungal treatment medicines; medicines for the treatment of cardiovascular diseases and disorders, colitis, muscle spasm, infectious diseases, acid-reflux disease, ulcer disease, and urological disorders; antibiotics; pharmaceutical products for the treatment of pain, thyroid disorders, gastrointestinal disorders, gastroesophageal disorders, inflammation, infections, fungal diseases and disorders, cardiovascular diseases and disorders, colitis, muscle spasm, attention deficit hyperactivity disorders, infectious diseases, acid-reflux disease, ulcer disease, and urological disorders having vancomycin, enalapril, lisinopril, and methotrexate as the active pharmaceutical ingredient; antacids; muscle relaxants; hormone replacement medicines; topical anti-inflammatory and ultrasound gels; pharmaceutical preparation for the treatment of pain, thyroid disorders, gastrointestinal disorders, gastroesophageal disorders, inflammation, infections, fungal diseases and disorders, cardiovascular diseases and disorders, colitis, muscle spasm, attention deficit hyperactivity disorders, infectious diseases, acid-reflux disease, ulcer disease, and urological disorders; pharmaceuticals for use in the treatment of cancer and autoimmune diseases and disorders, and for the treatment and prevention of renal, oncological, inflammatory, gastrointestinal, gastroesophageal, and cardio-vascular diseases and disorders
First Use Anywhere: 20250100
First Use in Commerce: 20250100

Classification

International Classes
005